Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forwardRaanana, Israel, ...

Polyrizon (PLRZ) announced the structuring of its clinical strategy for PL-14, the Company’s proprietary intranasal allergy blocker for ...

the Company’s proprietary intranasal allergy blocker for seasonal allergic rhinitis. The clinical strategy was updated in preparation for a planned pre-submission meeting with the U.S. Food and ...

Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced the structuring of its clinical ...

(RTTNews) - Polyrizon Ltd. (PLRZ), on Thursday, announced the structuring of its clinical strategy for PL-14, a proprietary intranasal allergy blocker for seasonal allergic rhinitis, ahead of its ...

(NASDAQ:PLRZ), a biotech firm focused on intranasal hydrogel technology, has announced the formulation of its clinical strategy for PL-14, a novel intranasal allergy blocker aimed at treating ...

Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced the structuring of its clinical ...

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm focused on intranasal hydrogel technology, has announced the formulation of its clinical strategy for PL-14, a novel intranasal allergy ...

This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025. The PL-14 allergy blocker is part of ...